No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
NARI Inari Medical
- 38.590
- -0.050-0.13%
Close Apr 19 16:00 ET
- 38.590
- 0.0000.00%
Post 16:52 ET
2.24BMarket Cap-1286333P/E (TTM)
39.145High38.010Low802.20KVolume38.510Open38.640Pre Close30.94MTurnover1.53%Turnover RatioLossP/E (Static)57.96MShares71.85052wk High4.81P/B2.02BFloat Cap37.92052wk Low--Dividend TTM52.39MShs Float127.420Historical High--Div YieldTTM2.94%Amplitude37.920Historical Low38.565Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Inari Medical(NARI.US) Director Sells US$58,040 in Common Stock
$Inari Medical(NARI.US)$ Director Hoffman William sold 1,451 shares of common stock on Apr 16, 2024 at an average price of $40 for a total value of $58,040.Source: Announcement What is statement of ch
Inari Medical to Announce First Quarter 2024 Financial Results
IRVINE, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other
Inari Medical(NARI.US) Officer Sells US$245.76K in Common Stock
$Inari Medical(NARI.US)$ Officer Hill, Mitch C. sold 6,000 shares of common stock on Apr 12, 2024 at an average price of $40.96 for a total value of $245.76K.Source: Announcement What is statement of
Express News | Inari Medical Inc : Truist Securities Cuts Target Price to $47 From $52
Needham Sees BSX, CNMD, RMD Beating Street, Despite Medtech Slow Down
Canaccord Genuity Maintains Buy on Inari Medical, Maintains $75 Price Target
Canaccord Genuity analyst William Plovanic maintains Inari Medical (NASDAQ:NARI) with a Buy and maintains $75 price target.
Comments
CEO Drew Hykes attributes Q4's robust revenue growth to healthy VTE procedure volumes, emerging therapies' traction, and strong international performance. He also highlights progress across all RCTs and the U.S. launch of LimFlow, emphasizing commitment to strong growth and operating profitability.
Press Release: Inari Medical Announces Preliminary 2023 Revenue and 2024 GuidanceThe appointment of Rhonda Robb, with her extensive experience and proven track record, is expected to lead Okami Medical into its next phase of expansion and growth, particularly as the company prepares to commercialize its LOBO Vascular Occlusion System.
The increased insider selling of Inari Medical stock over buying in the last three months along with the year-long trend of insider transactions indicate caution despite high insider ownership. Company risk factors should also be considered alongside insider behavior.
The future looks bleak with predicted negative returns; current investors should consider de-risking. For potential investors, a negative growth outlook raises the risk of holding the Inari Medical stock. Careful examination of further insights and warning signs is advised before investing.
ColumnsTop upgrades and downgrades on 6/21: XOM, ADBE, UAA, BEKE and more
Upgrades
• $ABM Industries(ABM.US$ : Baird Upgrades to Outperform from Neutral - PT $50
• $American Tower Corp(AMT.US$ : JPMorgan Upgrades to Overweight from Underweight - PT $285 (from $245)
• $Church & Dwight(CHD.US$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $95
• $Chewy(CHWY.US$ : Wedbush Upgrades to Outperform from Neutral - PT $35 (from $30)
• $Centene(CNC.US$ : Credit Suisse Upgrades to Outperform from...
• $ABM Industries(ABM.US$ : Baird Upgrades to Outperform from Neutral - PT $50
• $American Tower Corp(AMT.US$ : JPMorgan Upgrades to Overweight from Underweight - PT $285 (from $245)
• $Church & Dwight(CHD.US$ : Wells Fargo Upgrades to Overweight from Equal Weight - PT $95
• $Chewy(CHWY.US$ : Wedbush Upgrades to Outperform from Neutral - PT $35 (from $30)
• $Centene(CNC.US$ : Credit Suisse Upgrades to Outperform from...
16
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg